• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RIBAVIRIN Drug Record

  • Summary
  • Interactions
  • Claims
  • RIBAVIRIN chembl:CHEMBL1643 Approved

    Alternate Names:

    RIBAVARIN
    SCH 18908
    SCH-18908
    RIBOFLURANOSYL CARBOXAMIDE
    VIRAMID
    COPEGUS
    RIBASPHERE
    VIRAZID
    RIBAPAK
    REBETOL
    NSC-163039
    RIBAVIRIN
    VIRAZOLE
    TRIBAVIRIN
    RBV
    COPEGUS®
    RIBAVIRINUM
    1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE
    RIBAVIRINE
    1-BETA-D-RIBOFURANOSYL-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE
    VIRAZOLE®
    RIBAVIRINA
    chembl:CHEMBL1643
    rxcui:9344
    pubchem.compound:37542
    drugbank:00811
    chemidplus:36791-04-5

    Drug Info:

    (2 More Sources)

    Publications:

    Fouchier et al., The effects of ribavirin on the GTP level and the VIP receptor dynamic of human IGR39 cells., J. Recept. Signal Transduct. Res.
    McHutchison et al., 2005, A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C., Antivir. Ther. (Lond.)
    Gish, 2006, Treating HCV with ribavirin analogues and ribavirin-like molecules., J. Antimicrob. Chemother.
    Leyssen et al., 2006, The anti-yellow fever virus activity of ribavirin is independent of error-prone replication., Mol. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kamal AM et al., 2016, Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection., Rom J Morphol Embryol
    Morio K et al., 2016, Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C., Hepatol Res
    About F et al., 2015, Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study., PLoS One
    Maan R et al., 2015, ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection., PLoS One
    Pineda-Tenor D et al., 2015, Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis., J Transl Med
    Ampuero J et al., 2015, Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment., J Clin Virol
    Cusato J et al., 2015, VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia., Pharmacogenet Genomics
    Seto WK et al., 2013, Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection., J Viral Hepat
    Ogawa E et al., 2013, Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy., J Hepatol
    Azakami T et al., 2011, Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol
    Thompson AJ et al., 2011, Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR., Hepatology
    Suzuki F et al., 2011, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir., Hepatology
    Ochi H et al., 2010, ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients., Gastroenterology
    Thompson AJ et al., 2010, Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction., Gastroenterology
    Fellay J et al., 2010, ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C., Nature
    Lopez-Rodriguez R et al., 2011, Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C., Clin Pharmacol Ther
    Guido et al., 2006, Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C., Mod. Pathol.
    Lange CM et al., 2011, Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy., J Hepatol
    Romero-Gómez M et al., 2003, HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C., Am J Gastroenterol
    Farag RE et al., 2013, Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients., Arch Iran Med
    Morello J et al., 2010, Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection., J Infect Dis
    El-Khazragy N et al., 2018, IL-28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients., J Cell Biochem
    Sakhaee F et al., 2017, The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection., Infect Genet Evol
    Asnavandi M et al., 2017, EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C., Genes Immun
    Gauthiez E et al., 2017, A systematic review and meta-analysis of HCV clearance., Liver Int
    D'Offizi G et al., 2017, Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection., New Microbiol
    Sedighimehr P et al., 2017, IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C., Arch Virol
    Ranjan P et al., 2016, Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent., Indian J Med Microbiol
    Mansoor S et al., 2016, Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?, J Gen Virol
    El-Bendary M et al., 2015, Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4., Hepatogastroenterology
    Suzuki M et al., 2016, Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013., J Pediatr Gastroenterol Nutr
    Schwarz KB et al., 2016, Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C., J Pediatr Gastroenterol Nutr
    O'Brien TR et al., 2015, Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance., J Hepatol
    Holmes JA et al., 2015, The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3., Aliment Pharmacol Ther
    Fathy MM et al., 2015, Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients., Cytokine
    Nadia K et al., 2015, The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C., Gene
    Cariani E et al., 2016, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis., Pharmacogenomics J
    Zheng H et al., 2015, IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis., Clin Res Hepatol Gastroenterol
    Terczyńska-Dyla E et al., 2014, Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes., Nat Commun
    Knapp S et al., 2014, Detection of allele specific differences in IFNL3 (IL28B) mRNA expression., BMC Med Genet
    Hézode C et al., 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study., Gut
    Umemura T et al., 2014, KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C., Hum Immunol
    Manns M et al., 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet
    Eslam M et al., 2014, IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection., J Hepatol
    Forns X et al., 2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial., Gastroenterology
    Fujino H et al., 2014, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., J Gastroenterol
    Nozawa Y et al., 2014, Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients., Tissue Antigens
    Covolo L et al., 2014, The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection., Aliment Pharmacol Ther
    Tsubota A et al., 2014, Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b., J Gastroenterol Hepatol
    Ragheb MM et al., 2014, Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4., Liver Int
    Muir AJ et al., 2014, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens., Clin Pharmacol Ther
    Franco S et al., 2014, IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients., AIDS
    Piluso A et al., 2013, Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study., J Viral Hepat
    Stenkvist J et al., 2013, HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism., J Viral Hepat
    Pol S et al., 2013, Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure., J Hepatol
    Shimoyama Y et al., 2013, Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C., Hepatol Res
    Luo Y et al., 2013, Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis., Gene
    Riva E et al., 2012, Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients., J Viral Hepat
    Poordad F et al., 2012, Factors that predict response of patients with hepatitis C virus infection to boceprevir., Gastroenterology
    Kobayashi M et al., 2012, Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus., J Gastroenterol
    Antaki N et al., 2012, IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5., Gut
    de Castellarnau M et al., 2012, Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients., PLoS One
    Liu CH et al., 2012, Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy., Antivir Ther
    Venegas M et al., 2011, IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients., World J Gastroenterol
    Asselah T et al., 2012, IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C., J Hepatol
    Ridruejo E et al., 2011, Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin., Ann Hepatol
    Lyoo K et al., 2011, Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin., J Clin Virol
    Hayashi K et al., 2011, Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy., Liver Int
    Toyoda H et al., 2011, Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene., J Med Virol
    Giannini EG et al., 2011, IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin., Aliment Pharmacol Ther
    Lindh M et al., 2011, Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus., J Infect Dis
    Pineda JA et al., 2011, Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients., AIDS
    Labarga P et al., 2011, Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse., AIDS
    Hashimoto Y et al., 2011, Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol
    Coto-Llerena M et al., 2011, Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation., Am J Transplant
    Liao XW et al., 2011, Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population., Antivir Ther
    Lagging M et al., 2011, Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms., PLoS One
    Eurich D et al., 2011, Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation., Liver Transpl
    Moghaddam A et al., 2011, IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection., Hepatology
    Sakamoto N et al., 2011, Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b., J Med Virol
    Chen JY et al., 2011, IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection., Genes Immun
    Yu ML et al., 2011, Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients., Hepatology
    Scherzer TM et al., 2011, Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin., J Hepatol
    Kawaoka T et al., 2011, Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b., J Hepatol
    Sarrazin C et al., 2011, Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients., J Hepatol
    Hayes CN et al., 2011, HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut
    Medrano J et al., 2010, Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV., Clin Infect Dis
    Pineda JA et al., 2010, Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus., Clin Infect Dis
    Stättermayer AF et al., 2011, Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C., Clin Gastroenterol Hepatol
    Akuta N et al., 2010, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin., Hepatology
    Mangia A et al., 2010, An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response., Gastroenterology
    Montes-Cano MA et al., 2010, Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes., Hepatology
    Honda M et al., 2010, Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C., Gastroenterology
    Thompson AJ et al., 2010, Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus., Gastroenterology
    Rauch A et al., 2010, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study., Gastroenterology
    Suppiah V et al., 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy., Nat Genet
    Tanaka Y et al., 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C., Nat Genet
    Ge D et al., 2009, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance., Nature
    Cusato J et al., 2016, Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia., Pharmacogenet Genomics
    Pineda-Tenor D et al., 2014, FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients., BMC Med
    Shaker OG et al., 2011, Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients., Clin Chim Acta
    Panasiuk et al., 2005, [The apoptosis of hepatic tissues in hepatitis C]., Przegl Epidemiol
    Anatol et al., 2005, Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy., World J. Gastroenterol.
    Salcedo et al., 2005, The potential of angiogenesis soluble markers in chronic hepatitis C., Hepatology
    Toyoda et al., 2008, Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin., J. Viral Hepat.
    Haas SL et al., 2009, Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response., J Clin Immunol
    Kronenberger et al., 2007, Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C., Antivir. Ther. (Lond.)
    Mori N et al., 2017, IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C., Hepatol Res
    Homoncik et al., 2005, Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C., Aliment. Pharmacol. Ther.
  • RIBAVIRIN   IFNL4

    Interaction Score: 9.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30450628 28739427 28703131 28261910 28072888 27833958 27714501 27514956 27498543 27027531 26902034 26284539 26032235 25958342 25918016 25534433 25080450 24907224 24768758 24602923 24308755 24117654 24102823 24072198 23490377 23383658 23321318 23142377 22863269 22626609 22438096 22345656 21993426 21951981 21911885 21907615 21726252 21606533 21572301 21537116 21466653 21447862 21374656 21246582 21145807 21112657 21068134 20964522 20804372 20728570 20648473 20621700 20578254 20399780 19684573


    Sources:
    PharmGKB

  • RIBAVIRIN   IFNL3

    Interaction Score: 9.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30450628 28739427 28703131 28261910 28072888 27833958 27714501 27514956 27498543 26902034 26825765 26284539 26186989 26032235 26003758 25958342 25918016 25769643 25534433 25287681 25080450 24929144 24907224 24768758 24602923 24362944 24355007 24308755 24117654 24102823 24096968 24072198 23730840 23490377 23383658 23321318 23281610 23142377 22863269 22626609 22438096 22345656 22328925 22301466 21993426 21987611 21951981 21911885 21907615 21745312 21739446 21726252 21606533 21572301 21537116 21503910 21466653 21447862 21390311 21384511 21374656 21360545 21346780 21254157 21246582 21145807 21112660 21112657 21068134 20964522 20804372 20728570 20648473 20621700 20578254 20434452 20399780 20060832 19749758 19749757 19684573


    Sources:
    PharmGKB

  • RIBAVIRIN   ITPA

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27833958 26916827 26670100 26441325 26438033 26071337 25713999 23730840 23707372 21503919 21274861 21246582 20637204 20547162 20173735


    Sources:
    PharmGKB

  • RIBAVIRIN   KRT18

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17713161


    Sources:
    NCI

  • RIBAVIRIN   OASL

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21993426


    Sources:
    PharmGKB

  • RIBAVIRIN   CST3

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18637076


    Sources:
    NCI

  • RIBAVIRIN   MICB

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBAVIRIN   CYP27B1

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21145801


    Sources:
    PharmGKB

  • RIBAVIRIN   IMPDH1

    Interaction Score: 1.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Inosine-5'-monophosphate dehydrogenase 1 inhibitor
    Direct Interaction yes

    PMIDs:
    16152757 16293677 16421290 11752352


    Sources:
    ChemblInteractions TTD

  • RIBAVIRIN   CYP2R1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBAVIRIN   ANGPT2

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16104024


    Sources:
    NCI

  • RIBAVIRIN   FTO

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25367448


    Sources:
    PharmGKB

  • RIBAVIRIN   SLC28A2

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26071337


    Sources:
    PharmGKB

  • RIBAVIRIN   SCARB1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBAVIRIN   IL18

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19455410


    Sources:
    PharmGKB

  • RIBAVIRIN   VIP

    Interaction Score: 0.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8771530


    Sources:
    NCI

  • RIBAVIRIN   SLC29A1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20812847


    Sources:
    PharmGKB

  • RIBAVIRIN   VWF

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15644045


    Sources:
    NCI

  • RIBAVIRIN   HLA-A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23360626


    Sources:
    PharmGKB

  • RIBAVIRIN   HLA-B

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12873589 23360626


    Sources:
    PharmGKB

  • RIBAVIRIN   MMP1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16699498


    Sources:
    NCI

  • RIBAVIRIN   BCL2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21159314 16190549 15902734


    Sources:
    NCI PharmGKB

  • RIBAVIRIN   LDLR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21572301


    Sources:
    PharmGKB

  • RIBAVIRIN   HLA-C

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBAVIRIN   IL6

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBAVIRIN   SLC6A4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIBAVIRIN   CXCL8

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RIBAVIRIN   EGFR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28703131


    Sources:
    PharmGKB

  • RIBAVIRIN   RORC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RIBAVIRIN   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27139837 25713999


    Sources:
    PharmGKB

  • RIBAVIRIN   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RIBAVIRIN   ALDH1A1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: RIBAVIRIN

    • Version: 14-September-2017

    Alternate Names:
    C807 NCI drug code

    Drug Info:

    Publications:
    Fouchier et al., The effects of ribavirin on the GTP level and the VIP receptor dynamic of human IGR39 cells., J. Recept. Signal Transduct. Res.
    Salcedo et al., 2005, The potential of angiogenesis soluble markers in chronic hepatitis C., Hepatology
    Kronenberger et al., 2007, Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C., Antivir. Ther. (Lond.)

  • PharmGKB: ribavirin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lopez-Rodriguez R et al., 2011, Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C., Clin Pharmacol Ther
    Riva E et al., 2012, Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients., J Viral Hepat
    Shimoyama Y et al., 2013, Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C., Hepatol Res

  • DTC: RIBAVIRIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1643 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Ribavirin

    • Version: 2020.06.01

    Alternate Names:
    D0H3WI TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1643

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1643

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21